Results 1 to 10 of about 29,620 (204)

Plexiform neurofibroma. [PDF]

J Eur Acad Dermatol Venereol
Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 4, Page 693-694, April 2026.
Martins F, Figueiredo AC.
europepmc   +8 more sources

Imaging diagnosis of plexiform neurofibroma- unravelling the confounding features: A report of two cases

Radiology Case Reports, 2021
Peripheral nerve sheath tumors such as neurofibroma, comprise 5% of all benign soft tissue tumors and usually occur due to an underlying neurofibromatosis.
Shabnam Bhandari Grover
exaly   +4 more sources

Exuberant Plexiform Neurofibroma

Acta Médica Portuguesa, 2023
N/a.
Catarina Correia, Miguel Reis, Paulo Filipe   +2 more
doaj   +3 more sources

Features of CT and EUS in mesenteric plexiform neurofibroma with Neurofibromatosis type I: A case report

Radiology Case Reports, 2021
Plexiform neurofibroma(PNF) is a rare benign tumor of the peripheral nerve, belonging to a subtype of neurofibroma. PNF is common in the head, neck and trunk. It is uncommonly observed in the mesentery. We report a case of mesenteric PNF in a 64-year-old
Ye-ting Li, Bachelor's degree, Hao Chen, Master degree, Xue Ding, Master degree, Qian Wu, Bachelor's degree, Qiu-chen Guo, Master degree, Duan-min Hu, PhD, Feng-yun Zhong, PhD, Yong-you Wu, PhD, Guang-qiang Chen, Master degree   +8 more
doaj   +2 more sources

Clinical Efficacy of Selumetinib in Alleviating Neuropathic Pain Associated with Plexiform Neurofibroma: A Case Series. [PDF]

Genes (Basel)
Background: Selumetinib, an MEK inhibitor, was approved by the U.S. Food and Drug Administration in April 2020 and became reimbursable in Italy in January 2020, for treating patients aged ≥3 years with neurofibromatosis type 1 (NF1) complicated by ...
Miele G, Russo I, Filipponi L, Perrotta S, Maida E, Piluso G, Melone MAB, Santoro C.   +7 more
europepmc   +2 more sources

Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trial. [PDF]

Nat Med
The MEK inhibitor selumetinib induces objective responses and provides clinical benefit in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs). To evaluate whether similar outcomes were possible in adult patients, in
Gross AM, O'Sullivan Coyne G, Dombi E, Tibery C, Herrick WG, Martin S, Angus SP, Shern JF, Rhodes SD, Foster JC, Rubinstein LV, Baldwin A, Davis C, Dixon SAH, Fagan M, Ong MJ, Wolters PL, Tamula MA, Reid O, Sankaran H, Fang F, Govindharajulu JP, Browne AT, Kaplan RN, Heisey K, On TJ, Xuei X, Zhang X, Johnson BC, Parchment RE, Clapp DW, Srivastava AK, Doroshow JH, Chen AP, Widemann BC.   +34 more
europepmc   +2 more sources

Identification of the Determinants of Plexiform Neurofibroma Morbidity in Pediatric and Young Adult Neurofibromatosis Type 1 Patients: A Pilot Multivariate Approach. [PDF]

Cancers (Basel)
Simple Summary We studied a group of 90 patients with NF1-related plexiform neurofibromas (PNs) with an average age of 15.7 years and a follow-up period of 9.8 yrs.
de Brons B, Dhaenens B, van Minkelen R, Oostenbrink R.   +3 more
europepmc   +2 more sources

Challenging Management of Plexiform Schwannoma and Plexiform Neurofibroma

Journal of Craniofacial Surgery, 2021
Abstract Plexiform variants of neurofibromas and schwannomas are rare and typically arise in superficial soft tissues in the head and neck region. The treatment of these tumors is challenging and no generally accepted guidelines exist for their optimal management.
Nicoli, Taija K, Saat, Riste, Tarkkanen, Jussi, Kinnunen, Ilpo, Mäkitie, Antti A., Jero, Jussi   +5 more
openaire   +5 more sources

Hepatic plexiform neurofibroma a rare manifestation of neurofibromatosis type 1: A case report and literature review [PDF]

Radiology Case Reports
Neurofibromatosis type 1 (NF1) is a clinical diagnosis supported by characteristic radiological multisystem manifestations. NF1 commonly presents with cutaneous, musculoskeletal, and neurological findings, while abdominopelvic involvement is less ...
Omar Y. Alkhaja, MD, MBBS, Feras Shmeylan Alharbi, MD, MBBS, Mohammed Salem Wadani, MD, MBBS, Moayad Khalid Almaimani, Ahmed Aldraihem   +4 more
doaj   +2 more sources

Safety and efficacy of selumetinib in pediatric and adult patients with neurofibromatosis type 1 and plexiform neurofibroma. [PDF]

Neuro Oncol
Background The MEK inhibitor, selumetinib, reduces plexiform neurofibroma (PN) in pediatric patients with neurofibromatosis type 1 (NF1). Its safety and efficacy in adults with PN and effectiveness in other NF1 manifestations (eg, neurocognitive function,
Kim H, Yoon HM, Kim EK, Ra YS, Kim HW, Yum MS, Kim MJ, Baek JS, Sung YS, Lee SM, Lim HS, Lee BJ, Lim HT, Kim D, Yoon J, Bae H, Hwang S, Choi YH, Kim KA, Choi IH, Lee SW, Park SJ, Lee BH.   +22 more
europepmc   +2 more sources